<DOC>
	<DOCNO>NCT00004104</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Interferon alfa-2b may interfere growth tumor cell . PURPOSE : Randomized phase II trial compare effectiveness vaccine therapy plus interleukin-2 without interferon alfa-2b treating patient stage III melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Interleukin-2 With Without Interferon Alfa-2b Treating Patients With Stage III Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect interferon alfa-2b potentiation antimelanoma antibody cellular immune response induce immunization polyvalent melanoma vaccine interleukin-2 patient stage III malignant melanoma . II . Determine optimal dose interferon maximally stimulate response patient . III . Determine toxicity regimen patient . OUTLINE : This randomize study . Patients randomized vaccine treat control arm receive one two dos interferon alfa-2b plus vaccine . All patient receive polyvalent melanoma vaccine incorporate interleukin-2 liposome . The vaccine administer intradermally every 2 week 8 week , monthly 3 month , every 3 month total 2 year disease progression . Patients assign arm II III also receive interferon alfa-2b subcutaneously , one two dos , three time week 2 year . Patients follow survival . PROJECTED ACCRUAL : A total 32 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , surgically resect stage III melanoma Clinically positive node AND/OR At least 2 histologically positive node HLAA2 , A3 , A11 , A26 positive Intact cellular immunity evidence least 5 mm reaction 48 hour least 1 follow recall antigen : PPD Mumps Candida Streptokinase streptodornase OR able sensitize dinitrochlorobenzene PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 02 Life expectancy : At least 12 month Hematopoietic : WBC great 3500/mm3 Platelet count great 100,000/mm3 Hematocrit great 30 % Hepatic : Bilirubin le 2.0 mg/dL SGOT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Prothrombin time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No significant cardiovascular disease No uncontrolled hypertension No congestive heart failure No uncontrolled cardiac arrhythmia No active angina pectoris No myocardial infarction past 12 month Pulmonary : Other : No second malignancy except carcinoma situ cervix basal squamous cell skin cancer No autoimmune disease HIV negative No significant medical illness would preclude compliance At least 4 week since prior serious infection require antibiotic Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior melanoma vaccine No prior immunotherapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 2 week since prior glucocorticosteroids nonmalignant purpose No concurrent steroid Radiotherapy : No concurrent radiotherapy Surgery : At least 4 week ( 12 week ) since prior major surgery Other : No concurrent immunosuppressive drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>